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Özet: Akut rinosinüzit tedavisinde bitkisel t›bbi ürün
Sinupret ile mometazon furoat›n kombine kullan›m›n›n
etkinli¤i ve güvenilirli¤i
Amaç: Bitkisel t›bbi ürünlerin üst solunum yolu enflamasyonlar›ndaki
etkinli¤i bilinmektedir.  Güncel bilgilerimiz komplike olmayan akut ri-
nosinüzitte, intranazal kortikosteroidlerin semptomlar› iyileﬂtirdi¤ini
desteklemektedir. Bu çal›ﬂmadaki amac›m›z, hafif ve orta ﬂiddetteki akut
rinosinüzitte mometazon furoat sprey ve oral bitkisel ilaç Sinupret'in
birlikte kullan›m›n› mometazon furoat sprey monoterapisi ile karﬂ›laﬂ-
t›rmakt›r.
Yöntem: K›rk alt› akut rinosinüzitli hasta iki gruba ayr›ld›. Grup 1
(n=23) günde 3 kez Sinupret, 160 mg oral ve günde 2 kez mometazon
furoat sprey 200 μg kulland›. Grup 2 (n=23) ise sadece  7 gün süreyle
günde 2 kez mometazon furoat sprey 200 μg kulland›. Çal›ﬂmada teda-
vi öncesi ve sonras› semptomlar ayr› ayr› (nazal obstrüksiyon, rinore,
postnazal ak›nt›, fasiyal a¤r› koku bozuklu¤u), toplam semptom skoru
ve endoskopik bulgular (mukoza ödemi ve mukoprülan sekresyon)  de-
¤erlendirildi.  
Bulgular: Tedavi sonras› her iki tedavi grubundaki tüm klinik para-
metrelerde düzelme gözlendi (p<0.000). MFNS/Sinupret grubunda
MFNS grubundan daha düﬂük toplam semptom skoru  (p=0.002), bu-
run t›kan›kl›¤› (p=0.001), burun ak›nt›s› (p=0.001), yüz a¤r›s›
(p=0.001), koku bozuklu¤u (p=0.002), mukozal ödem (p=0.003) ve
mukopürulan ak›nt› (p=0.001) oldu¤u gözlemlendi. MFNS/Sinupret
grubunda hiç bir yan etki görülmezken, sadece MFNS grubunda 1
hastada hafif epistaksis ve 1 burun kurulu¤u gözlendi. 
Sonuç: Sonuçlar›m›z akut rinosinüzitte MFNS/Sinupret kombine te-
davisinin semptomlar ve endoskopik bulgular üzerinde daha etkili oldu-
¤unu göstermiﬂtir. MFNS monoterapisine k›yasla hiçbir advers olay
bildirilmemiﬂtir.
Anahtar sözcükler: Glukokortikoidler, inflamasyon, t›bbi bitki, rinit,
sinüzit.
Abstract
Objective: Herbal medicinal products have a well-established role in
therapy of upper airway inflammations. Current evidence supports the
use of intranasal corticosteroids for improvement in clinical symptoms
of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate effi-
cacy and safety of combined therapy by mometasone furoate nasal spray
(MFNS) and oral herbal medicinal product Sinupret in comparison to
MFNS monotherapy when treating mild to moderate ARS.  
Methods: Forty-six ARS patients were divided into two groups. Group
1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily
and MFNS 200 μg twice daily for 7 days. Group 2 (n=23) received only
MFNS 200 μg twice daily for 7 days. We assessed total symptom score
(TSS), individual symptom scores for each symptom (nasal obstruction,
rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell)
and endoscopic findings (mucosal edema, mucopurulent secretion),
before and after treatment. 
Results: Significant improvement of all clinical parameters was found
after both treatment modalities (p<0.000). We observed lower post-treat-
ment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001),
facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema
(p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret
group than in MFNS group. We found no adverse events in MFNS/
Sinupret group, while only 1 patient reported mild epistaxis and 1 patient
reported dryness in the nose in MFNS Group.
Conclusion: Our results suggest better efficacy of combined
MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic
findings, with the absence of adverse events in comparison to MFNS
monotherapy. 
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Acute rhinosinusitis (ARS) is an inflammatory disease with
a sudden onset including the mucosal membrane of
paranasal sinuses and both nasal cavities. About 98 to 99.5%
of the cases of ARS are caused by viruses, especially rhi-
noviruses, coronaviruses, parainfluenza, and influenza virus-
es, and adenoviruses.[1] Secondary bacterial infection is
observed in about 0.5 to 2% of cases.[2] The pathophysiolo-
gy of ARS is complex with a dominant role of inflammato-
ry mucosal swelling, confining of natural sinus ostia in the
area of ostiomeatal complex and sphenoethmoidal recess,
and impaired mucociliary transport.[3] Viral infections dis-
turb the function of ciliated cells of the pseudostratified res-
piratory epithelium, leading to mucociliary clearance
impairment. This results in increase of cytokine and
chemokine production, neutrophil chemoattraction, and
bradykinin and leukotrienes releases. Therefore, vessel
dilatation leads to higher mucosal swelling. Transudation
and mucosal gland secretion accumulation within the sinus-
es favor the development of bacteria which release toxins to
develop inflammation, leading to a cruel circle effect.[3]
Antibiotics are the most common treatment agents in
ARS. However, as ARS is mostly a viral disease, the moder-
ate benefits of antibiotics should be weighed against associ-
ated risks such as allergic reactions, gastrointestinal diseases
and the development of resistant bacterial germs.[4] There is
a reasonable evidence of use of intranasal corticosteroids in
the treatment of ARS. Meltzer et al.[5] demonstrated the effi-
cacy of mometasone furoate nasal spray as an effective
monotherapy in uncomplicated ARS, maintaining a propos-
al to decrease recommending antibiotics for patients pre-
senting with these clinical outcomes. The other authors
suggest the use of steroid and a topical antibiotic combina-
tion into the nasal cavity healing uncomplicated bacterial
ARS.[6]
Herbal medicines have been used for centuries for the
treatment of many disorders. However, to date there are
only several controlled, randomized analyses which evaluat-
ed the effectiveness of herbal medicine in therapy of ARS.
Sinupret is a trademarked herbal preparation developed in
Germany, available in tablet and drop forms, and composed
of five herbal extracts: gentian (Gentiana lutea, root); prim-
rose (Primula veris, flower); common sorrel (Rumex acetosa,
herb); elder (Sambucus nigra, flower); European vervain
(Verbena officinalis, herb). Previous investigations clearly
demonstrated mucolytic, secretomotoric, anti-inflammato-
ry, antiviral and antibacterial effects of this medicinal prod-
uct.[7–10] These characteristics, as well as the results of two
double-blind, placebo-controlled studies recommended the
use of Sinupret as a good treatment option in both ARS and
chronic rhinosinusitis (CRS).[11,12] The aim of our study was
to evaluate the efficacy and safety of combined mometasone
furoate nasal spray (MFNS) and oral Sinupret therapy in
comparison to MFNS monotherapy when treating mild to
moderate ARS. To our knowledge, this is the first such
study presented in the literature.  
Materials and Methods
Study design
This was a non-interventional, non-placebo controlled, case-
control study of two consecutive case series, based on the
treatment of ARS. We conducted a retrospective analysis of
prospectively collected data at three institutions from January
to December 2016. This investigation was conducted in
accordance with the Declaration of Helsinki. The local
Ethics Committee approved the study protocol (MFVMA06/
16-18/) and we obtained written informed consent from each
patient.
Study participants
Forty-six (n=46) adult patients with diagnosis of ARS
according to the criteria of the European Position Paper on
Rhinosinusitis and Nasal Polyps (EPOS 2012),[13] aged from
18 to 61 years were enrolled in the study. Patients had
inflammation of the nasal cavity/paranasal sinuses for 7 or
more days and less than 12 weeks with at least two of the
following symptoms: nasal obstruction, anterior nasal secre-
tion/postnasal drip, facial pain/pressure, and/or impaired or
loss of the sense of smell. On nasal endoscopic examination,
patients could have mucosal edema and mucopurulent
secretion predominantly in the middle meatus. 
The patients were divided into two groups. Group 1
(n=23) received herbal medicinal product Sinupret® forte
tablets of 160 mg (Bionorica, Neumarkt, Germany), three
times daily and MFNS (Nasonex®, Merck Sharp & Dohme,
Hertfordshire, UK) 200 μg twice daily (two puffs in each
nostril in the morning and in the evening) for 7 days. Group
2 (n=23) received only MFNS 200 μg twice daily for 7 days. 
Exclusion criteria were: younger than 18 and older than
65 years, CRS with or without nasal polyps, nasal/paranasal
sinus surgery within 6 months before study, nasal septum
deviation and/or middle turbinate hypertrophy significant-
ly impairing nasal airflow and corticosteroid spray applica-
tion, systemic diseases affecting the nose (cystic fibrosis,
Churg-Strauss syndrome, Wegener’s granulomatosis, etc.),
seasonal allergic rhinitis, bronchial asthma, aspirin sensitiv-
ity, hypersensitivity to study medications, the use of oral or
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topical antibiotics, antihistamines, corticosteroids and
leukotriene antagonists within the four weeks before the
start of the study, the use of mucolytics, decongestants and
analgesics within the 7 days before the investigation, preg-
nancy and lactation, diabetes mellitus, and smoking.
Subjects were excluded if they had symptoms or signs of
severe bacterial ARS (fever >38°, persistent severe unilater-
al facial or tooth pain, facial swelling, profuse unilateral
mucopurulent secretion). 
Clinical evaluation
Intensity of 5 rhinosinusitis symptoms (nasal obstruction,
rhinorrhea, postnasal drip, facial pain/pressure, impaired
sense of smell) was assessed at the start of the study (visit 1)
and within the two days after the end of investigation (visit
2) using a visual analogue scale (VAS) (0–10 cm; from
0=absent to 10=maximum intensity). Patients indicating
their symptoms’ score to be from 0 to 3 were diagnosed as
“mild ARS”. Symptoms in the score range from 4 to 7 were
diagnosed as “moderate ARS” while the score from 8 to 10
with fever of above 38°C for at least 3 days were diagnosed
as “severe ARS”. The patients with severe disease were
excluded from investigation.
At visits 1 and 2, a rhinologist with proven experience in
nasal endoscopy used a 4 mm 0° endoscope to evaluate the
presence of mucosal edema and mucopurulent secretion in
the middle meatus. A four-point scales were used for assess-
ment of endoscopic findings: mucosal edema scored from
0=no edema to 3=severe edema; mucopurulent secretion
from 0=none to 3=profuse. The maximum endoscopic score
is 6, bilaterally for each endoscopic sign. According to the
EPOS 2012 recommendations, radiological examinations
(X-ray, CT, and MRI) or bacteriological examination were
not used in the diagnostics of ARS.[13]
During the investigation, patients recorded their symp-
tom scores on diary cards twice daily, in the morning and in
the evening, and the same specialist recorded scores at the
visit 2.  
The efficacy endpoints were mean total symptom score
(TSS; sum of the scores for nasal obstruction, rhinorrhea,
postnasal drip, facial pain/pressure, impaired sense of
smell), individual symptom score (score for each nasal
symptom) and endoscopic score for each sign (mucosal
edema, mucopurulent secretion), at the visit 1 and visit 2. 
Safety
Reported adverse events were recorded throughout the
study, with severity grades as mild, moderate and severe. At
visit 2, nasal examination, laboratory tests and vital signs
assessment were performed. Therefore, the development of
any medical complications associated with progression of
rhinosinusitis (orbital, endocranial or bone complications)
were also recorded during the study. 
Statistical analysis
The parameters have been expressed as mean±standard
deviation. For between-group comparison, a non-paramet-
ric Mann-Whitney U test was used. The paired compar-
isons within a group were performed using the Wilcoxon’s
test. P values <0.05 were considered significant. The analy-
sis was performed by using the SPSS software (Statistical
Package for the Social Sciences, version 15.0; SPSS Inc.,
Chicago, IL, USA).  
Results
Forty-six patients (26 men and 20 women), aged between
18 and 61 years (mean age 41.06±28.91) diagnosed with
ARS were included in this investigation. All numerical
data presenting the demographic characteristics, total
symptom score, individual symptom scores and endoscop-
ic findings (mucosal edema, mucopurulent secretion),
before and after two different treatment modalities are
presented in Table 1. Results concerning all parameters’
statistical significances before and after the MFNS and
MFNS/Sinupret treatment are presented in Table 2.  
At the visit 1, we found no significant difference regard-
ing the TSS, nasal obstruction score, rhinorrhea score,
postnasal drip score, facial pain/pressure score and loss of
the sense of smell score (p>0.05 for all parameters) between
two investigation groups. We also found no significant dif-
ference between the MFNS and MFNS/Sinupret group
regarding the mucosal edema (p>0.05) and mucopurulent
secretion (p>0.05) (Table 1).
After the treatment, we found highly significant decrease
of all clinical parameters in both MFNS and MFNS/
Sinupret groups (p<0.000 for all parameters) (Figs. 1–3). 
At the visit 2, we observed significantly lower levels of
TSS (p=0.002), nasal obstruction score (p=0.001), rhinor-
rhea score (p=0.001), facial pain/pressure score (p=0.001),
impaired sense of smell score (p=0.002), mucosal edema
(p=0.003) and mucopurulent secretion (p=0.001) in
MFNS/Sinupret group than in MFNS group. On the other
hand, we found significantly lower postnasal drip score
(p=0.018) in ARS patients receiving only MFNS in compar-
ison to those receiving MFNS and Sinupret (Table 1). 
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The safety of two different treatment modalities was
also evaluated. None of the patients of MFNS/Sinupret
group reported any adverse events, and all their vital signs
and laboratory tests were normal. Among the participants
of MFNS group, 1 patient had mild epistaxis and 1 patient
reported the sense of dryness in the nose. All patients in
this group had normal vital signs and laboratory tests.  
Discussion
Currently, nasal corticosteroid has turn out to be a con-
ventional adjuvant therapy in the treatment of both ARS
and CRS. Pharmacologically, novel nasal steroids [i.e.
MFNS and fluticasone propionate (FPNS)] seem to have
considerably advanced lipid solubilities and topical poten-
cies, and reduced systemic bioavailabilities than old gener-
ation nasal steroids.[14] Previous investigations with
patients suffering from uncomplicated ARS suggest that
MFNS can be better monotherapy option than antibiotic
therapy.[5] MFNS 200 μg twice daily monotherapy is well
accepted and extensively stimulated excessive alleviation of
utmost ARS symptoms compared with placebo and amox-
icillin.[5] The results of our study demonstrated that 7-days
MFNS monotherapy improves all nasal symptoms and
endoscopic findings in patients with uncomplicated form
of ARS. However, we also showed that combined use of
herbal drug Sinupret with MFNS improve the efficacy of
ARS treatment regarding the almost all symptoms and
local signs of acute sinonasal inflammation. The results
suggest that addition of Sinupret to MFNS leads to better
improvement of nasal obstruction, rhinorrhea, facial
Parameter MFNS (n=23) MFNS+Sinupret (n=23) p-value
mean±SD (range) mean±SD (range)
Male/female 13/10 13/10 1.000
Age 42.70±2.43 (18–61) 40.39±2.60 (18–61) 0.524
Nasal obstruction (B) 6.48±0.14 (5–7) 6.13±0.21 (4–7) 0.299
Nasal obstruction (A) 3.00±0.15 (2–4) 2.09±0.06 (2–3) 0.001
Rhinorrhea (B) 6.61±0.10 (6–7) 6.22±0.17 (5–7) 0.094
Rhinorrhea (A) 4.13±0.13 (3–5) 3.30±0.18 (2–5) 0.001
Postnasal drip (B) 6.43±0.16 (4–7) 6.43±0.12 (5–7) 0.701
Postnasal drip (B) 2.87±0.10 (2–4) 3.30±0.15 (2–5) 0.018
Facial pain/pressure (B) 6.70±0.15 (4–7) 6.48±0.11 (6–7) 0.052
Facial pain/pressure (A) 2.96±0.13 (2–4) 1.91±0.11 (1–3) 0.001
Impaired sense of smell (B) 6.35±0.12 (5–7) 6.13±0.17 (5–7) 0.402
Impaired sense of smell (A) 3.04±0.13 (2–4) 2.04±0.12 (1–3) 0.001
Total symptom score (B) 32.57±0.41 (29–35) 31.39±0.53 (26–34) 0.078
Total symptom score (A) 15.17±0.40 (12–19) 13.48±0.25 (12–16) 0.002
Mucosal edema (B) 5.61±0.10 (5–6) 5.52±0.12 (4–6) 0.682
Mucosal edema (A) 2.70±0.13 (1–4) 2.22±0.09 (2–3) 0.003
Mucopurulent secretion (B) 4.83±0.16 (4–6) 4.96±0.15 (4–6) 0.522
Mucopurulent secretion (A) 2.87±0.11 (2–4) 1.83±0.14 (1–3) 0.001
A: after treatment, B: before treatment, MFNS: mometasone furoate nasal spray, SD: standard deviation 
Table 1. Demographic characteristics of study population and clinical parameters before and after therapy.  
Parameter MFNS MFNS+Sinupret
Nasal obstruction (B-A) -3.46 (p<0.000) -4.05 (p<0.000)
Rhinorrhea (B-A) -2.09 (p<0.000) -3.30 (p<0.000)
Postnasal drip (B-A) -3.54 (p<0.000) -3.13 (p<0.000)
Facial pain/pressure (B-A) -3,74 (p<0.000) -4.57 (p<0.000)
Impaired sense of smell (B-A) -3.31 (p<0.000) -4,09 (p<0.000)
Total symptom score (B-A) -17.4 (p<0.000) -17.91 (p<0.000)
Mucosal edema (B-A) -2,91 (p<0.000) -3.3 (p<0.000)
Mucopurulent secretion (B-A) -1.96 (p<0.000) -3.15 (p<0.000)
B-A: before treatment-after treatment, MFNS: mometasone furoate nasal spray
Table 2. Radiologic findings of patients with paranasal sinus fungus ball.
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pain/pressure and impaired sense of smell, as well as bet-
ter resolution of mucosal edema and mucopurulent secre-
tion from the nasal middle meatus. Therefore, TSS is sig-
nificantly lower after the combined treatment in compari-
son to MFNS monotherapy. 
Sinupret has been developed using the extraction of
the phytopharmaceuticals contained in five herbs: gentian
(Gentiana lutea), primrose (Primula veris), common sorrel
(Rumex acetosa), elder (Sambucus nigra), and European ver-
vain (Verbena officinalis). The antiinflammatory action of
Sinupret has been demonstrated in experimentally
induced pleural inflammation in rats. The rats in which
this herbal drug was administered orally one hour before
treatment showed a lower volume of pleural effusion, less
infiltration of polymorphonuclear leukocytes and
decreased levels of prostaglandins in the exudates.[15] This
antiinflammatory effect can be attributed to the polysac-
charides and tannins in sorel and the iridoids in vervain.[15]
Also, Sinupret has antiviral effect against adenoviruses,
human rhinoviruses, respiratory syncytial virus, coxsack-
ievirus, influenza and parainfluenza virus.[9] The mecha-
nism of this action is inhibition of  neuraminidase, an
important enzyme for process of viral replication.[9]
Sinupret has bactericidal effects on Gram-positive and
Gram-negative bacteria, but this medication is not effec-
tive against Escherichia coli.[10] These antiinflammatory and
antimicrobial effects of Sinupret lead to a better reduction
of nasal obstruction, rhinorrhea, facial pain and impaired
sense of smell in patients on combined therapy. The bet-
ter resolution of mucopurulent middle meatus discharge
in our patients from MFNS/Sinupret group can be
explained by antibacterial action of this herbal drug.  
However, after the treatment (visit 2), our patients
receiving MFNS alone had lower postnasal drip score in
comparison with those treating with Sinupret and MFNS.
Fig. 1. Total symptom score (TSS), before and after two different treat-
ment modalities. A: after treatment; B: before treatment; MFNS: mome-
tasone furoate nasal spray; TSS: total symptom score.
Fig. 2. Mucosal edema, before and after two different treatment moda-
lities.
Fig. 3. Mucopurulent secretion from the middle nasal meatus, before and
after two different treatment modalities. 
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This finding is not in accordance with lower rhinorrhea
and mucopurulent secretion score in MFNS/Sinupret
group after the treatment. Besides the fact that in patients
with ARS/CRS clinical findings sometimes are not in
accordance with subjective senses, this interesting phe-
nomenon could be explained by strong secretolytic and
secretomotoric activity of Sinupret. Dysfunctional
mucociliary transport is a common pathophysiologic
process developed as a results of infection and inflamma-
tion in ARS and CRS. Transport of the mucus layer with-
in the airway surface liquid covering respiratory epithelia
is influenced by the transepithelial secretion of ions, espe-
cially chloride ions (Cl-). Primary Cl- channel in respira-
tory epithelium responsible for good mucoliliary transport
is the ’cystic fibrosis transmembrane conductance regula-
tor’ (CFTR), which is dysfunctional or absent in patients
with cystic fibrosis resulting in a significant reduction of
ciliary beat frequency.[7,16] Improvement of mucociliary
clearance represents an important therapeutic strategy for
patients with sinonasal inflammation by accelerating clear-
ance of inflammatory products and pathogenic bacteria.
Bioflavonoids, the main pharmacological components in
Sinupret, strongly activate transepithelial Cl- secretion in
airway epithelial cells resulting in hydration of airway sur-
face liquid and reduction of nasal fluid viscosity.[7,16]
Therefore, Sinupret stimulates the ciliary beat frequency
of human epithelial cells in vitro, with a significant
increase only 10 minutes post-application and dose-
dependent effects lasting up to 1 hour.[8] So, in patients
treated with Sinupret and MFNS, accelerate nasal fluid
clearance and low nasal secretion viscosity annul the
inhibitory corticosteroid effects on mucosal gland secre-
tion and inflammatory exudation, resulting in subjective
sense of increased postnasal drip. Accordingly, the patients
with combined therapy have higher postnasal drip score in
the post-treatment period in comparison to ARS patients
treated only by MFNS.  
We observed no adverse events in patients from
MFNS/Sinupret group in contrary to two participants from
MFNS group which had the mild epistaxis and the sense of
dryness in the nasal cavity. Nasal corticosteroid treatment
have an antiinflammatory effect and inhibitory effect on
nasal mucosa gland secretion. The application of the double
dose of MFNS (400 μg daily) in patients with ARS could
result in a mild level of nasal epithelium atrophy and con-
secutive mild nasal bleeding. The results of an experimental
animal study by Yaremchuk et al.[17] demonstrated that
Sinupret oral drops applied during acute rhinitis attenuate
atrophic and destructive changes of the ciliated epithelium.
This could be an explanation of a protective role of Sinupret
in combined treatment of ARS. 
Conclusion
Our results demonstrated better efficacy of combined
MFNS/Sinupret therapy on nasal obstruction, rhinorrhea,
facial pain/pressure and impaired sense of smell, as well as
on endoscopic findings in patients with ARS in compari-
son to MFNS monotherapy. The absence of adverse
events suggests a better safety of combined treatment
comparing to nasal corticosteroid monotherapy in patients
with uncomplicated form of ARS.   
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